Table 7.
Relapse characteristics
| Authors | Diagnostic method primary infection | Treatment primary infection | Dosage primary infection | PQ therapy primary infection? | Time between primary infection and 1st relapse (weeks) | Diagnostic method 1st relapse | Treatment 1st relapse | PQ therapy 1st relapse? | Time between 1st and 2nd relapse (weeks) | Diagnostic method 2nd relapse | Treatment 2nd relapse | PQ therapy 2nd relapse? | Time between 2nd and 3rd relapse (weeks) | Treatment 3rd relapse |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bottieau [28] | MIC | Quinine | 1.5 g/day for 5 days | Y, “standard regimen” (presumably 15 mg/day for 14 days) | 7 | MIC | Chloroquine 1.5 g over 3 days | Y, 7 mg/kg over 3 weeks | NA | NA | NA | NA | NA | NA |
| Doxycycline | 100 mg/day for 7 days | |||||||||||||
| – | Quinine–doxycycline | – | Y, “standard regimen” | 2 | – | Chloroquine, dosage unknown | Y, 10 mg/kg over 4 weeks | NA | NA | NA | NA | NA | NA | |
| – | Chloroquine | – | N | 60 | – | Atovaquone–proguanil, dosage unknown | Y, 5 mg/kg over 6 weeks | 78 | MIC | Atovaquone–proguanil, then chloroquine | Y, 8 mg/kg over 3 weeks | NA | NA | |
| Collins et al. [29] | MIC | Chloroquine | 1.5 g over 3 days | N | 22 | MIC | Chloroquine, dosage unknown | N | 17 | MIC | Chloroquine, dosage unknown | – | NA | NA |
| MIC | Chloroquine | 1.5 g over 3 days | N | 10 | MIC | – | – | NA | NA | NA | NA | NA | NA | |
| MIC | Chloroquine | 1.5 g over 3 days | N | 15 | MIC | – | – | NA | NA | NA | NA | NA | NA | |
| MIC | Chloroquine | 1.5 g over 3 days | N | 24 | MIC | – | – | NA | NA | NA | NA | NA | NA | |
| MIC | Chloroquine | 1.5 g over 3 days | N | 20 | MIC | – | – | NA | NA | NA | NA | NA | NA | |
| Nathwani et al. [30] | MIC | Chloroquine | 15 mg/day for 14 days | Y, 15 mg/day for 14 days | 17 | MIC | Chloroquine 1.5 g over 3 days | Y, 30 mg/day for 21 days | NA | NA | NA | NA | NA | NA |
| Chin et al. [31] | MIC | Quinine sulphate | 650 mg 8-hourly for 5 days | N | – | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | 5 | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | – | Quinine sulphate 650 mg 8-hourly for 5 days |
| MIC | Quinine sulphate | 650 mg 8-hourly for 5 days | N | 2 | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | 20 | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | NA | NA | |
| MIC | Quinine sulphate | 650 mg 8-hourly for 5 days | N | 36 | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | NA | NA | NA | NA | NA | NA | |
| MIC | Quinine sulphate | 650 mg 8-hourly for 5 days | N | – | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | – | MIC | Quinine sulphate 650 mg 8-hourly for 5 days | N | NA | NA | |
| MIC | Chloroquine | 600 mg single dose | N | – | MIC | Chloroquine 600 mg single dose | N | – | MIC | Chloroquine 600 mg single dose | Y, 15 mg/day for 14 days | NA | NA | |
| Garnham et al. [32] | MIC | Chloroquine | – | N | 15 | MIC | No treatment | N | 10 | MIC | No treatment | N | NA | NA |
| MIC | Chloroquine | – | N | 14 | MIC | No treatment | N | 14 | MIC | No treatment | N | NA | NA | |
| Jeffery [33] | MIC | Chloroquine | – | N | 21 | MIC | Chloroquine, dosage unknown | N | 22a | MIC | – | – | NA | NA |
| MIC | chloroquine | – | N | 34 | MIC | chloroquine, dosage unknown | Y, dosage unknown | NAa | NA | NA | NA | NA | NA |
MIC microscopy, Y yes, N no, NA not applicable, – not mentioned in the original publication
aThe patient who did not receive primaquine treatment for his 1st relapse developed a second one, however it was not clear from the article, which one of the two patients developed the described second relapse